Home
About
FAQ
History (15)
Diverse metabolic profiles of a Streptomyces strain isolated from a hyper-arid environment.
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
Integrins and the endometrium: new markers of uterine receptivity.
Multicountry Distribution and Characterization of Extended-spectrum ß-Lactamase-associated Gram-negative Bacteria From Bloodstream Infections in Sub-Saharan Africa.
Pharmacoeconomic considerations in treating actinic keratosis.
See All 15 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Pharmacoeconomic considerations in treating actinic keratosis.
Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics. 2009; 27(6):451-64.
View in:
PubMed
subject areas
Cost of Illness
Cost-Benefit Analysis
Economics, Pharmaceutical
Health Care Costs
Humans
Keratosis, Actinic
authors with profiles
Steven R. Feldman MD, PhD